Abstract

We have treated a rare case of elderly relapsed/refractory (R/R) duffuse large B cell lymphoma (DLBCL) with hemophagocytic lymphohistiocytosis (HLH) and SARS-CoV-2 infection, which achieved complete response (CR) without lymphoma-related symptoms after polatuzumab vedotin/bendamustine/rituximab (pola-BR) treatment. To the best of our knowledge, this is the first report of R/R DLBCL with HLH and Covid-19 treated with pola-BR, and the patient is still alive at the time of report. We found that polatuzumab vedotin may have a potential therapeutic effect on HLH and Covid-19.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.